New strategies for the treatment of breast cancer

Breast Cancer

Volumn 8, Issue 4, 2001, Pages 265-274

  Bentrem, David J ^a   O'Regan, Ruth M ^a   Craig Jordan, V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anti estrogens; Breast cancer; Raloxifene; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SEGMENTAL MASTECTOMY; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; PROGNOSIS; RALOXIFENE; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0035753323     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967523     Document Type: Article

References (80)

1. Levenson AS, Jordan VC: Selective Oestrogen Receptor Modulation: Molecular pharmacology for the millennium. Eur J Cancer 35:1628-1639, 1999. (Pubitemid 30050631)
2. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001.
3. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001. (Pubitemid 32176267)
4. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group [see comments]. J Natl Cancer Inst 88:1543-1549, 1996.
5. Early Breast Cancer Trials Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467, 1998.
6. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989. (Pubitemid 19062522)
7. Fisher B, Redmond C: Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr 11:105-116, 1992.
8. EFisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [see comments]. J Natl Cancer Inst 88:1529-1542, 1996. (Pubitemid 26374506)
9. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690, 2001. (Pubitemid 32492809)
10. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998. (Pubitemid 28439961)
11. Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876-1881, 2000.
12. Bergman L, Beelen ML, Gallee MP, et al: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356:881-887, 2000.
13. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comments]. N Engl J Med 326:852-856, 1992.
14. Love RR, Barden HS, Mazess RB, et al: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588, 1994. (Pubitemid 24362409)
15. Turken S, Siris E, Seldin D, et al: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086-1088, 1989. (Pubitemid 19175144)
16. Kristensen B, Ejlertsen B, Dalgaard P, et al: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12:992-997, 1994. (Pubitemid 24145328)
17. Zidan J, Keidar Z, and Israel O: Effect of tamoxifen on bone metabolism in postmenopausal women with early stage breast cancer. In: ASCO, San Francisco, May 12, 2001, p1845, 2001.
18. Cauley JA, Norton L, Lippman ME, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134, 2001. (Pubitemid 32193616)
19. Gradishar W, Glusman J, Lu Y, et al: Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88:2047-2053, 2000. (Pubitemid 30233206)
20. Snyder KR, Sparano N, and Malinowski JM: Raloxifene hydrochloride. Am J Health Syst Pharm 57:1669-1675; quiz 1676-1678, 2000.
21. O'Regan RM, Gajdos C, Dardes R, et al: Effect of raloxifene after tamoxifen on breast and endometrial cancer growth. In: Proceedings of ASCO, San Francisco, CA. Abstract 95, May 12, 2001, 2001.
22. Kuiper GG, Enmark E, Pelto-Huikko M, et al: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930, 1996. (Pubitemid 26190778)
23. Hall JM, McDonnell DP: The estrogen receptor betaisoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens [In Process Citation]. Endocrinology 140:5566-5578, 1999. (Pubitemid 30645344)
24. Shang Y, Hu X, Di Renzo J, et al: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852, 2000.
25. Paech K, Webb P, Kuiper GG, et al: Differential ligand activation of estrogen receptors ERalpha and ERbeta at API sites [see comments]. Science 277:1508-1510, 1997. (Pubitemid 27449239)
26. Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31:129-138, 1994. (Pubitemid 24264219)
27. Catherino WH, Wolf DM, and Jordan VC: A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 9:1053-1063, 1995.
28. Levenson AS, Catherino WH, and Jordan VC: Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 60:261-268, 1997. (Pubitemid 27278057)
29. Levenson AS, Tonetti DA, and Jordan VC: The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 77:1812-1819, 1998. (Pubitemid 28254616)
30. Brzozowski AM, Pike AC, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758, 1997. (Pubitemid 27458965)
31. Shiau AK, Barstad D, Loria PM, et al: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937, 1998. (Pubitemid 29019045)
32. Jiang SY, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor [see comments]. J Natl Cancer Inst 84:580-591, 1992.
33. Levenson AS, Jordan VC: The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58:1872-1875, 1998. (Pubitemid 28217461)
34. MacGregor Schafer J, Liu H, Bentrem DJ, et al: Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 60:5097-5105, 2000.
35. Bentrem D, Dardes R, Liu H, et al: Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 142:838-846, 2001. (Pubitemid 32222434)
36. Liu H, Lee ES, De los Reyes A, et al: Silencing and reactivation of the selective estrogen receptor modulator (SERM)-ER complex. Cancer Res, (in press).
37. Pike AC, Brzozowski AM, Walton J, et al: Structural insights into the mode of action of a pure antiestrogen. Structure (Camb) 9:145-153, 2001. (Pubitemid 32215278)
38. Jordan VC, Koch R: Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone. Endocrinology 124:1717-1726, 1989. (Pubitemid 19105438)
39. Dauvois S, Danielian PS, White R, et al: Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041, 1992.
40. Gibson MK, Nemmers LA, Beckman WC, Jr., et al: The mechanism of ICI 164, 384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129:2000-2010, 1991.
41. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995.
42. Milla-Santos A, Milla L, Rallo L, et al: Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 65:119-124, 2001. (Pubitemid 32193615)
43. Holli K, Valavaara R, Blanco G, et al: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18:3487-3494, 2000.
44. Sato M, Turner CH, Wang T, et al: LY353381. HC1: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287:1-7, 1998. (Pubitemid 29140178)
45. MacGregor-Schafer J, Lee E-S, Dardes R, et al: Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY 353381) and LY 117018 in tamoxifen-stimulated breast cancer xenografts. Clin Cancer Res 7:2505-2512, 2001. (Pubitemid 32751656)
46. Baselga J, A L-C, Belief M, et al: Randomized doubleblind phase II study of a selective estrogen receptor modulator (SERM) LY 353381 in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 57:31, 1999.
47. Labrie F, Labrie C, Belanger A, et al: EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 69:51-84, 1999. (Pubitemid 29305845)
48. Schafer JI, Liu H, Tonetti DA, et al: The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res 59:4308-4313, 1999. (Pubitemid 29418748)
49. Willson TM, Henke BR, Momtahen TM, et al: 3-[4-(1,2-Diphenylbut-1-enyl) phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 37:1550-1552, 1994. (Pubitemid 24195466)
50. McDonnell DP, Clemm DL, Hermann T, et al: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-69, 1995.
51. Willson TM, Norris JD, Wagner BL, et al: Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:3901-3911, 1997. (Pubitemid 27351945)
52. Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 112:R7-10, 1987. (Pubitemid 17020887)
53. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989. (Pubitemid 19207240)
54. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750, 1995.
55. Gottardis MM, Ricchio ME, Satyaswaroop PG, et al: Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50:3189-3192, 1990. (Pubitemid 20190116)
56. O'Regan RM, Cisneros A, England GM, et al: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth [see comments]. J Natl Cancer Inst 90:1552-1558, 1998. (Pubitemid 28535720)
57. Howell A, De Friend D, Robertson J, et al: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer [see comments]. Lancet 345:29-30, 1995.
58. Howell A, Osborne CK, Morris C, et al: ICI 182, 780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 89:817-825, 2000.
59. Simpson ER, Zhao Y, Agarwal VR, et al: Aromatase expression in health and disease. Recent Prog Horm Res 52:185-213, 1997. (Pubitemid 127470211)
60. Santen RJ, Santner SJ, Pauley RJ, et al: Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol 61:267-271, 1997. (Pubitemid 27455688)
61. De Jong PC, de Ven JV, Nortier JWR, et al: Inhibition of intratumoural aromatase activity and estradiol by exemestane in postmenopausal breast cancer patients: results of a double blind randomised study. In: ASCO, San Francisco, May 12, 2001, p130, 2001.
62. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001. (Pubitemid 32119104)
63. Kvinnsland S, Anker G, Dirix LY, et al: High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 36:976-82, 2000. (Pubitemid 30316421)
64. Kaufmann M, Bajetta E, Dirix LY, et al: Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. Results Of a double-blind randomised phase III trial. Eur J Cancer 36 Suppl 4:S86-87, 2000.
65. Buzdar A: Exemestane in advanced breast cancer. Anticancer Drugs 11:609-616, 2000.
66. Nabholtz JM: Steroidal side effects of exemestane. J Clin Oncol 19:2107-2108, 2001.
67. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000.
68. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000.
69. Donnellan PP, Douglas SL, Cameron DA, et al: Aromatase inhibitors and arthralgia. J Clin Oncol 19:2767, 2001.
70. Howell A, Anderson E, Blarney R, et al: The primary use of endocrine therapies. Recent Results Cancer Res 152:227-244, 1998.
71. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000. (Pubitemid 30399188)
72. Paepke S, Apffelstaedt J, Eremin J, et al: Neoadjuvant treatment of postmenopausal breast cancer patients with letrozole: a randomized multicenter study versus tamoxifen. In: Second European Breast Cancer Conference, Brussels, Belgium, September 26, 2000, p179, 2000.
73. Ellis MJ: Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea. Cancer Control 7:557-562, 2000.
74. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998. (Pubitemid 28135586)
75. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366, 2001. (Pubitemid 32642188)
76. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001. (Pubitemid 32451796)
77. Dixon JM, Love CDB, Bellamy C, et al: Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66 (3):191-199, 2001. (Pubitemid 32675021)
78. Yue W, Santen RJ: Aromatase inhibitors: rationale for use following antiestrogen therapy. Semin Oncol 23:21-27, 1996. (Pubitemid 26320223)
79. Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988.
80. Lohrisch C, Paridaens R, Dirix Y, et al: No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin in 1st line treatment of metastatic breast cancer: companion study to a european organization of research and treatment of cancer trial with Pharmacias' Upjohn. In: ASCO, San Francisco, CA May 12, 2001, p167, 2001.